Novo Nordisk's AI Bet and Buyback Blitz Amid a Year of Pressure

Novo Nordisk's stock, trading at €33.59, is caught in a powerful crosscurrent. While the Danish pharmaceutical giant aggressively buys back its own shares and advances a promising new drug, the market remains deeply skeptical, with the share price down roughly 25% since the start of the year. This divergence highlights a company navigating significant operational headwinds while betting heavily on its own future.

The company is ploughing billions into its own equity. By mid-April, Novo Nordisk had purchased over 12 million B shares in the current tranche, spending approximately 3.1 billion Danish kroner at an average price of nearly 257 kroner per share. This brings the company's total holdings of its own stock to nearly 30 million shares, representing 0.7% of its total share capital. These repurchases are part of a much larger plan to remove shares worth up to 15 billion kroner from the market by February 2027.

This capital return program unfolds against a challenging financial outlook. For 2026, management anticipates a currency-adjusted decline in both sales and operating profit, with the drop expected to be between 5% and 13%. The pressures are multifaceted: pricing erosion, reduced cost coverage for its drugs under US health programs, and generic competition as patents for the key drug semaglutid expire in markets like Canada and China. CEO Mike Doustdar has labeled 2026 the "year of price pressure."

In response to these commercial challenges, Novo Nordisk is pursuing a strategic overhaul on multiple fronts. The company is reshaping its workforce, hiring around 2,000 new employees this year with a strict focus on research and production for core therapies. This follows a reduction of approximately 10% of positions, or 7,800 jobs, the previous year. Voluntary turnover is expected to offset the new hires, keeping the overall headcount stable.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

Beyond internal restructuring, the pharma giant is looking outward for an edge. A newly announced partnership with OpenAI aims to turbocharge drug discovery. Novo Nordisk plans to use artificial intelligence to analyze complex datasets and accelerate promising compounds to market, with pilot projects launching soon and full integration of the AI systems targeted by the end of 2026. While financial terms were not disclosed, the move underscores the intense competitive pressure from rivals like Eli Lilly.

Simultaneously, the company's pipeline is delivering positive news. Its drug etavopivat for sickle cell disease successfully met all primary endpoints in a pivotal Phase 3 trial. The US FDA has already granted the therapy accelerated review pathways, and Novo Nordisk plans to submit its marketing application in the second half of 2026.

Yet, these strategic and clinical advances have so far failed to impress investors. The stock's closing price of €33.59 sits well below its 200-day moving average. A Relative Strength Index (RSI) reading of 24.6 indicates the shares are deeply oversold. The company is also actively engaging on the political front, spending around $1.3 million on US lobbying in the first quarter of 2026 to address issues from drug reimbursement to patent protections.

Novo Nordisk at a turning point? This analysis reveals what investors need to know now.

The coming weeks will be critical. Novo Nordisk is set to report its quarterly results in May, providing the first concrete evidence of whether its political efforts and strategic shifts can cushion the anticipated margin decline. For now, the company's massive share buyback program stands as a stark declaration of management's confidence, even as the market demands more proof.

Ad

Novo Nordisk Stock: New Analysis - 22 April

Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated Novo Nordisk analysis...

en | DK0062498333 | NOVO | boerse | 69234074 |